Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
Taysha Gene Therapies, Inc. reported voting results from its 2026 annual meeting of stockholders. Of 287,341,999 shares outstanding on the record date, 243,857,812 shares, or about 84.86%, were present or represented by proxy, indicating strong participation.
Stockholders elected Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. as directors to serve until the 2029 annual meeting. They also ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, with 243,814,085 votes in favor.
On a non-binding basis, stockholders approved the compensation of the named executive officers and expressed a preference to hold future advisory votes on executive pay every year. The company plans to hold these say-on-pay votes annually unless the board later determines a different frequency is in stockholders’ best interests.
Taysha Gene Therapies reported that Vestal Point Capital, LP and Ryan Wilder beneficially hold 18,000,000 shares of common stock, representing 6.3% of the class based on 287,269,885 shares outstanding as of March 19, 2026.
The ownership is reflected as shared voting and dispositive power over the 18,000,000 shares. The filing is an amendment to a Schedule 13G, signed by Ryan Wilder on May 15, 2026.
Taysha Gene Therapies reports beneficial ownership disclosure by RTW Investments and Roderick Wong. The Reporting Persons state shared voting and dispositive power over 20,689,084 shares, representing 7.0% of the class based on 287,269,885 shares outstanding as of March 19, 2026. The amounts "assume the exercise of Warrants held by the Reporting Persons to purchase 7,008,836 Shares." The filing identifies the Reporting Persons' business address and notes the RTW Funds hold the economic right to dividends and sale proceeds.
Taysha Gene Therapies reported a wider quarterly loss as it increased investment in gene therapy programs and collaboration revenue ended. For the three months ended March 31, 2026, revenue was $0 compared with $2.3 million a year earlier, when Astellas research revenue was recognized.
Research and development expense rose to $33.8 million from $15.6 million, and general and administrative expense increased to $9.7 million from $8.2 million, driving a net loss of $42.4 million versus $21.5 million. Operating cash outflow was $40.9 million. Cash and cash equivalents were $276.6 million, with total cash, cash equivalents and restricted cash of $279.3 million and total assets of $300.4 million. Management believes this cash will fund planned operations for at least twelve months. The company also carries a $50.0 million Trinity term loan measured at fair value and had an accumulated deficit of $753.7 million.
Taysha Gene Therapies reported first quarter 2026 results and progress on its Rett syndrome gene therapy TSHA-102. The company reaffirmed FDA alignment on its BLA pathway, including pivotal REVEAL trial design, endpoints and the potential to file based on a six-month interim analysis.
Research and development expenses were $33.8 million, up from $15.6 million a year earlier, reflecting BLA-enabling PPQ manufacturing and higher clinical spending on the REVEAL and ASPIRE trials. General and administrative expenses were $9.7 million, compared with $8.2 million.
Taysha reported a net loss of $42.4 million, or $0.12 per share, versus a $21.5 million loss, or $0.08 per share, in the prior-year quarter. The company ended March 31, 2026 with $276.6 million in cash and cash equivalents and expects this to fund planned operating expenses into 2028.
Taysha Gene Therapies, Inc. is asking stockholders to vote at its June 1, 2026 virtual annual meeting on four items: electing two directors, ratifying Deloitte & Touche LLP as auditor, approving executive pay on an advisory basis, and choosing how often to hold future say‑on‑pay votes.
The record date is April 8, 2026, with 287,341,999 common shares entitled to one vote each and a majority of shares required for quorum. The board highlights its mix of independent and management directors, committee structure, insider‑trading and hedging policies, and detailed 2025 executive pay, equity awards, and potential severance on termination or change in control.
Taysha Gene Therapies, Inc. President and Head of R&D Nagendran Sukumar exercised employee stock options for 19,021 shares of common stock at an exercise price of $1.71 per share and sold 200,000 common shares at a weighted average price of $4.46 per share. The sale occurred in multiple trades between $4.335 and $4.625 and was made pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025. Following these transactions, he directly holds 1,136,410 shares of common stock and 455,920 stock options.
Taysha Gene Therapies filed a Form 144 reporting a proposed sale of 200,000 shares by Sukumar Nagendran. The filing lists a sale date of 01/12/2026 and a gross amount of $942,740 tied to those shares. The disclosure also lists prior grants: 131,550 RSUs, 49,429 RSUs, and 19,021 stock options with grant dates shown in 2024 and 2025.
Taysha Gene Therapies is a clinical-stage biotech focused on AAV9 gene therapies for severe central nervous system diseases, led by TSHA-102 for Rett syndrome. The company is running REVEAL and ASPIRE trials to support a potential broad label in patients aged 2 years and older.
In Part A of the REVEAL Phase 1/2 trials, 12 females aged 6‑21 years received TSHA-102, with 10 evaluable patients showing 22 developmental milestones gained or regained and 165 additional functional skills and improvements across communication, fine motor, gross motor and autonomic function. An 83% response rate at six months was observed in the high-dose cohort, with clinically meaningful R-MBA and CGI-I improvements and no treatment-related serious adverse events or dose-limiting toxicities as of March 2026.
The pivotal single-arm REVEAL Part B trial will enroll 15 females aged 6 to <22 years at the high dose (1x10^15 total vg), using milestone gain/regain as the primary endpoint with a 6‑month interim analysis that may support a biologics license application. The ASPIRE study in 2 to <4‑year‑olds will provide safety data for label expansion. TSHA-102 has multiple regulatory designations, including orphan drug, rare pediatric disease, Fast Track, RMAT, Breakthrough Therapy and U.K. ILAP, and Taysha is aligning Chemistry, Manufacturing and Controls and PPQ campaigns to enable a planned BLA. The company also discloses earlier-stage programs TSHA-113 for tauopathies and TSHA-114 for Fragile X syndrome, and outlines its licensing and intellectual property framework.